Celosia Therapeutics is focused on developing innovative gene therapies aimed at addressing neurodegenerative diseases that currently lack effective treatment options. Their approach leverages a deep understanding of the molecular pathways involved in conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease, frontotemporal dementia, and Dravet Syndrome. The company is actively working on a therapeutic pipeline that includes a proprietary genetic medicine known as CTx1000, which targets the toxic form of the TDP-43 protein, a key player in the pathology of several neurodegenerative diseases. By utilizing the cell's own degradation mechanisms, CTx1000 aims to restore neuronal health and functionality.

The technology behind CTx1000 is designed to selectively bind to the mislocalized and toxic aggregates of TDP-43, tagging them for degradation through the ubiquitin-proteasome system. Preclinical studies in symptomatic mouse models have shown promising results, including a significant increase in survival rates and a delay in the onset of paralysis. Celosia Therapeutics plans to advance its research through preclinical studies over the next few years, with the goal of initiating human trials, thereby contributing to the evolving landscape of treatments for devastating neurodegenerative diseases.

Australia

Celosia Therapeutics is a privately held pre-clinical stage gene therapy company, developing solutions for neurodegenerative diseases that have limited alternative therapeutic options.

Celosia Therapeutics

Company Details